Patent: 6,680,168

Summary for Patent: 6,680,168

Title:	Passive immunization against clostridium difficile disease
Abstract:	The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.
Inventor(s):	Thomas, Jr.; William D. (Somerville, MA), Giannasca; Paul J. (Newton, MA), Zhang; Zhenxi (Cambridge, MA), Lei; Wende (Cambridge, MA), Monath; Thomas P. (Harvard, MA)
Assignee:	Acambis, Inc. (Cambridge, MA)
Application Number:	09/815,452
Patent Claims:	see list of patent claims

US Patent 6,680,168: Claim Scope and U.S. Patent Landscape for “Hyperimmune C. difficile Toxin-Neutralizing Immune Globulin” via Toxoid Administration

What does US Patent 6,680,168 claim for producing human hyperimmune C. difficile toxin-neutralizing immune globulin?

Core invention (claim 1): a two-step method for generating a human-derived hyperimmune immune globulin that neutralizes Clostridium difficile toxins, using a human already positive for C. difficile neutralizing antibodies, then isolating the immune globulin.

Claim 1 elements

1. Subject matter: “human hyperimmune Clostridium difficile toxin-neutralizing immune globulin.”
2. Method step A (key conditioning step): administer a C. difficile toxoid to a human that already has C. difficile neutralizing antibodies.
3. Method step B: isolate from that same human the toxin-neutralizing immune globulin.

Claim 2 adds composition scope

• The toxoid contains a toxoid of toxin A and a toxoid of toxin B.

How courts typically construe these claim features

• “Administering a Clostridium difficile toxoid” focuses on the antigen identity (toxoid A/B) and administration to humans, not animals.
• “already has C. difficile neutralizing antibodies” is a population precondition. It narrows the method to boosting or enriching an existing antibody repertoire, rather than first eliciting immunity from a naïve subject.
• “Isolating … from said human” ties the method to collection from the treated individual, which typically maps to plasmapheresis or blood collection followed by IgG/immune globulin purification.

Practical interpretation for product strategy

This patent is structured like a human-source immune globulin enrichment/collection method tied to toxoid boosting. That means infringement and validity analysis should be centered on:

• the clinical protocol (toxoid administration to antibody-positive humans),
• the target immune globulin (neutralizing for toxin A and/or toxin B),
• and the manufacturing workflow (human collection and isolation).

Which claim interpretation risk points drive enforceability for US 6,680,168 in litigation?

High-risk claim construction points

• “Already has” neutralizing antibodies: If an accused process uses antibody screening/selection, the patent can read in. If it uses universally immunizes antibody-naïve donors, the scope may not be met.
• Definition of “toxoid”: If the accused product uses live/attenuated material, recombinant fragments, or non-toxoid antigens, claim 1 can be avoided. If it uses detoxified toxin variants intended to be non-toxic immunogens, it can be implicated.
• Neutralizing immune globulin identity: If the accused immune globulin is produced via engineered monoclonals, hybridomas, recombinant antibodies, or affinity-purified fractions not characterized as “immune globulin” from the treated human, the claim may not be met.
• Isolation “from said human”: Process steps that outsource collection to third-party donor pools or use pooled plasma without a direct tie to the treated individual can become factual dispute areas, depending on how strictly “said human” is construed.

What patents protect “hyperimmune” C. difficile toxin-neutralizing immune globulin in the U.S.?

US 6,680,168 is a method claim focused on human toxoid administration to antibody-positive individuals followed by isolation. The relevant surrounding landscape usually splits into four patent buckets:

1) Toxoid compositions for C. difficile (toxin A and toxin B)

Patents in this bucket typically cover:

• detoxified toxin A/B or toxoid variants,
• combinations for bivalent immunity,
• formulation and adjuvants,
• methods of making toxoids.

These can matter for 6,680,168 because claim 2 locks to toxoid A + toxoid B. If a third party uses only toxin A toxoid, it can avoid claim 2 while potentially still implicating claim 1.

2) Human hyperimmunization and passive immunization workflows

Other patents often target:

• selecting donors with existing anti-C. difficile neutralizing antibodies,
• plasmapheresis and enrichment steps,
• IgG purification and fractionation,
• QC assays and neutralizing activity characterization.

These can overlap with claim 1’s central method structure.

3) Immune globulin products for C. difficile (composition and use)

Downstream patents more often claim:

• composition of immune globulin or IgG fractions with defined neutralizing capacity,
• therapeutic formulations and dosing regimens,
• combinations with other agents,
• method-of-use (prophylaxis or treatment in patients with C. difficile infection).

Those are adjacent but not identical. A composition/use estate can still constrain enforcement strategy even if the 6,680,168 method claim is narrow.

4) Antibody technologies that bypass “human toxoid administration”

If a competitor makes antibodies by:

• recombinant expression,
• monoclonals (hybridoma-derived and engineered),
• IVIG-like collections not conditioned as claimed, then it may avoid 6,680,168, shifting the battle to other patents.

When does US 6,680,168 expire, and what does that mean for generic and biosimilar risk?

US Patent Term: For a U.S. utility patent issued in 2004, the baseline term is typically 20 years from the earliest effective non-provisional filing date, subject to adjustments or reductions. Without the underlying filing data (earliest priority and PTA/PTE), an exact expiration date cannot be calculated from the provided information alone.

Licensing and launch implications: If the term is still active, it can block:

• licensing of the method to third-party plasma collection and purification protocols that match claim 1,
• and method-based manufacturing claims in related agreements.

If fully expired, the market risk shifts from enforcement to whether trade secret or know-how dominates manufacturing.

What generic entry risks exist for a method patent like US 6,680,168?

A “method of producing” immune globulin patent does not behave like a simple dosage form patent. Generic risk depends on whether an ANDA competitor or follow-on manufacturer uses the same manufacturing protocol.

Likely enforcement targets

• Contract plasma collection programs that implement toxoid boosting in antibody-positive donors.
• Manufacturers licensing toxoid administration protocols tied to specific neutralizing profiles.
• Any process that can be reconstructed from:
  • donor selection criteria,
  • clinical protocol documents,
  • manufacturing SOPs,
  • and in-process analytics.

Design-around pathways

• Use antibody-negative donors and generate antibodies de novo (avoid “already has”).
• Use antigen types that are not “toxoid.”
• Produce antibodies by recombinant or monoclonal routes.
• Isolate IgG/immune globulin from donors but without toxoid administration as defined.

How do claim 1 and claim 2 compare to typical “toxoid + immune response” patents?

Claim 1 is narrower than toxoid immunization claims because it adds:

• a pre-existing antibody condition, and
• human-source isolation tied to that condition.

Claim 2 narrows toxoid identity to bivalent toxin A/B toxoids. Many toxoid patents cover broader detoxified constructs or only one toxin component.

What would an infringement analysis for US 6,680,168 focus on?

An infringement case typically turns on whether the accused program matches all claim limitations.

Factual map for claim 1

1. Does the accused process administer a C. difficile toxoid?
2. Are recipients donors already antibody-positive for C. difficile neutralizing antibodies?
3. Is the immune globulin isolated from that treated human?
4. Is it “toxin-neutralizing immune globulin” within the claim’s functional scope (neutralizes C. difficile toxins).

Factual map for claim 2

• Does the toxoid comprise both toxin A toxoid and toxin B toxoid?

What is the patent strength of US 6,680,168 given its narrow method framing?

Strength drivers

• The claim is not broad to all antibody therapies. It is anchored to:
  • toxoid administration,
  • a pre-existing antibody-positive donor,
  • and isolation from that human.
• That can improve defensibility against prior art that focuses on immunization of naïve subjects, animal models, or non-toxoid antigens.

Vulnerability drivers

• Narrow method claims can be easier to design around.
• Functional language like “neutralizing” often invites factual disputes and could be challenged through:
  • lack of clear definition,
  • prior art immune globulins with neutralizing activity,
  • and obviousness arguments combining toxoid vaccination and passive antibody generation.

How does the patent landscape shift to FDA and product-regulatory paths for C. difficile immune globulin?

Method patents can still be relevant post-approval, but enforcement usually depends on whether:

• the marketed product is produced using the claimed human toxoid boosting and isolation workflow, and
• FDA manufacturing descriptions, comparability protocols, or public CMC disclosures tie back to the claim steps.

Regulatory implication: If an approved passive immunization product is made from animal-derived antibodies, recombinant antibodies, or monoclonals, claim 1’s “isolate from said human after toxoid administration” limitation weakens infringement exposure.

Which companies are likely implicated by US 6,680,168’s manufacturing model?

Without a verified linkage to:

• specific licensed toxoid boosting programs,
• donor selection criteria (“already has neutralizing antibodies”),
• and human collection/manufacturing workflows, any company list would be speculative.

What is the Orange Book status of US 6,680,168?

US patents that are method claims for producing immune globulin are commonly not listed in the Orange Book unless tied to an approved small-molecule drug with NDA linkage. Immune globulin products for infectious diseases, if approved, typically sit in different regulatory frameworks (biologics/licensing under BLAs) and are listed in the Orange Book only when relevant to drug approval linkages.

A definitive Orange Book status requires mapping the patent to a specific FDA approval (application/labeling) and is not determinable from the provided claim text alone.

Patent estate strategy: how to evaluate freedom to operate around claim 1

A credible FTO screen for a program involving C. difficile toxin-neutralizing immune globulin should segment into:

1. Toxoid composition patents (toxin A/B toxoid scope)
2. Donor selection and hyperimmune collection method patents (antibody-positive preconditioning)
3. Purification/fractionation patents (IgG/immune globulin isolation from human plasma)
4. Product use and formulation patents (therapeutic application and dosing)
5. Competing antibody technology patents (monoclonals/recombinants that bypass the toxoid-enrichment method)

US 6,680,168 is most likely to be a constraint in bucket (2) and partially (3).

Key Takeaways

• US 6,680,168 claim 1 is a human-specific method: administer a C. difficile toxoid to a human already holding C. difficile neutralizing antibodies, then isolate toxin-neutralizing immune globulin from that same human.
• Claim 2 limits the toxoid to both toxin A and toxin B components.
• The patent is narrow in a way that can be protective versus prior art immunizing naïve subjects, but it is also design-around friendly by changing donor selection, antigen type, and antibody generation technology.
• Infringement risk is driven by verifiable process facts: donor antibody status, toxoid identity, and the isolation workflow from treated humans.

FAQs

1) Is US 6,680,168 limited to plasmapheresis-based manufacturing?
The claim requires isolation from “said human,” which is consistent with plasma/whole blood collection workflows, but “isolation” is not limited in the provided claim text to any single collection technology.

2) Can a process that uses toxin A toxoid alone avoid claim 2?
Yes. Claim 2 expressly requires toxoids of both toxin A and toxin B, though claim 1 could still be implicated depending on how the “toxoid” is defined and whether the method also uses a qualifying bivalent toxoid.

3) What happens if donors are immunized from antibody-negative status?
Such a process can avoid the “already has … neutralizing antibodies” limitation, which is central to claim 1.

4) Does claim 1 cover recombinant or monoclonal antibody production?
The claim is framed as isolation of immune globulin from a treated human after toxoid administration. Recombinant or monoclonal routes can fall outside the “administer toxoid to antibody-positive human and isolate from said human” structure.

5) Does this patent cover therapeutic use in patients?
The provided claims are manufacturing method claims, not method-of-use claims for treating C. difficile infection, so patient treatment may be controlled by different patents.

References

1. United States Patent 6,680,168. “Method of producing human hyperimmune Clostridium difficile toxin-neutralizing immune globulin,” claims 1-2. (Patent document).

Details for Patent 6,680,168

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134	January 11, 1944		2021-03-22
Grifols Therapeutics Llc	GAMMAKED, GAMUNEX-C	immune globulin injection (human) 10% caprylate/chromatography purified	Injection	125046	August 27, 2003		2021-03-22
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	May 21, 2004		2021-03-22
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	March 26, 2007		2021-03-22